Medizinisches Versorgungszentrum DermaKiel GmbH
- Address
- lock Available on a paid plan
Immune System Diseases and Skin and Connective Tissue Diseases
At Medizinisches Versorgungszentrum DermaKiel GmbH in Kiel, clinical research focuses on inflammatory and allergic conditions affecting the skin and immune system. The studies are mainly designed to test new treatments, assess long-term safety, and better understand how these diseases can be controlled over time.
- Research in atopic dermatitis is evaluating whether new therapies can improve symptom control and support longer-term disease management.
- Trials in moderate-to-severe plaque psoriasis are examining treatment effectiveness, safety, and durability of response for people living with chronic skin inflammation.
- Studies in hidradenitis suppurativa are testing whether emerging therapies can reduce disease activity and improve patient outcomes.
This area reflects a strong emphasis on chronic dermatologic and immune-mediated diseases, with a clear focus on improving both symptom relief and long-term treatment safety.
Allergic and Urticarial Disorders
The site also supports research into chronic spontaneous urticaria, cold-induced urticaria, and symptomatic dermographism. These trials are aimed at reducing flare activity, improving day-to-day comfort, and identifying therapies that may offer better control for patients with persistent hives and related allergic skin conditions.
- Studies are evaluating new options for chronic spontaneous urticaria to see whether they can lower overall disease activity.
- Research in cold-induced urticaria and symptomatic dermographism is exploring whether treatment can improve responses to physical triggers.
These investigations highlight a practical goal: finding more effective ways to manage recurring urticaria and related hypersensitivity disorders.
Wound Healing and Skin Repair
Another important research focus at this hospital/clinic involves venous leg ulcer care. The clinical studies are assessing whether new approaches can improve wound cleansing, prepare the wound bed more effectively, and support healing in patients with chronic leg ulcers.
- Trials in venous leg ulcer are testing treatments intended to support wound debridement and better healing conditions.
- The research aims to improve treatment effectiveness for chronic wounds that are often difficult to manage.
This work adds a wound-care dimension to the site’s broader dermatology portfolio, with emphasis on practical improvements in healing outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Celldex Therapeutics Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celldex Therapeutics Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinisches Versorgungszentrum DermaKiel GmbH
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic Dermographism | Celldex Therapeutics Inc. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 3 | Unknown | 2024-12-16 | 2026-04-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.